Larimar Therapeutics, Inc.
LRMR
$3.47
$0.3511.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -207.84% | -21.06% | -99.82% | -121.84% | -71.00% |
| Total Depreciation and Amortization | 18.92% | 0.00% | 10.00% | -4.94% | -2.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 602.53% | 169.58% | -32.16% | -7.14% | -84.15% |
| Change in Net Operating Assets | 287.57% | -23.36% | -38.59% | 149.61% | -537.85% |
| Cash from Operations | -17.14% | -38.55% | -154.92% | -133.49% | -166.80% |
| Capital Expenditure | 62.90% | 93.07% | -- | -9.15% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.88% | 129.83% | 121.21% | 886.04% | 158.87% |
| Cash from Investing | 21.07% | 129.68% | 121.13% | 830.20% | 158.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 217,523.33% | -- | -- | -- | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 217,523.33% | -- | -- | -- | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,423.69% | 99.31% | -114.50% | 78.43% | 104.96% |